All In Biotech

NDA 021143 · Sun Pharma Canada

Trivagizole 3

Clotrimazole · Vaginal · Azole Antifungal

Last checked: Nov 20, 2026Latest source record: Aug 25, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Apr 12, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

127

31 Phase 3, 11 recruiting

FAERS reports

11,742

9,093 serious, 938 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 30, 2025.

Uses treats vaginal yeast infections relieves external itching and irritation due to a vaginal yeast infection

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TRIVAGIZOLE 3 · CLOTRIMAZOLE 2% · CREAM, VAGINAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Clotrimazole" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,384
  • nausea825
  • macular degeneration812
  • pain783
  • off label use769
  • headache754
  • dyspnoea727
  • fatigue660
  • diarrhoea619
  • pyrexia528
  • malaise483
  • rash478

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200484
2005114
2006135
2007113
2008122
2009150
2010169
2011229
2012346
2013217
2014297
2015453
2016630
2017589
2018790
2019965
2020866
2021993
2022931
2023893
20241,008
20251,037
2026610

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 342 on PubMed

Sponsor: Sun Pharma Canada

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.